Format

Send to

Choose Destination
Cell Oncol. 2006;28(5-6):223-32.

The expression and action of decay-accelerating factor (CD55) in human malignancies and cancer therapy.

Author information

1
Department of Haematology-Oncology, University of Muenster, Germany.

Abstract

Decay-accelerating factor (DAF, CD55) is physiologically acting as an inhibitor of the complement system, but is also broadly expressed in malignant tumours. Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. Therefore, DAF has already become a target for therapy. In this paper we review the role of DAF in human malignancies as described in different basic, diagnostic and experimental therapeutic studies.

PMID:
17167176
PMCID:
PMC4618202
DOI:
10.1155/2006/814816
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for IOS Press Icon for PubMed Central
Loading ...
Support Center